IndustryCompany release

Auditor flags going-concern doubt at Marea and M2 despite $75.3M cash

🇺🇸 Lisata Therapeutics, Inc. (LSTA) · Thu 12 Nov 2026

Ernst & Young's report on the combined 2025 and 2024 accounts of Marea Therapeutics and M2 Therapeutics cites recurring losses and a net stockholders' deficit.

Ernst & Young has included a going-concern warning in its audit report on the combined financial statements of Marea Therapeutics and M2 Therapeutics. The report is dated 12 November 2026 and is addressed to the stockholders of Lisata Therapeutics.

The auditor says the companies' recurring losses and net stockholders' deficit raise substantial doubt about their ability to continue as a going concern. The report covers the combined financial statements for 2025 and 2024.

The companies' cash rose to $75.3M at 31 December 2025, from $31.6M a year earlier. They reported an accumulated deficit of $141.3M at the same date.

For context, a going-concern paragraph is an auditor's statement that conditions in the accounts cast significant doubt on whether an entity can keep operating for the foreseeable future. It is not a finding that the entity will fail. The material available does not say how the companies plan to address the doubt.

What it means for your team

  • Teams assessing Marea or M2 as partners, licensors or suppliers may want to factor the auditor's going-concern language into counterparty risk reviews.
  • A higher year-end cash balance did not remove the auditor's doubt, so cash alone is not a sufficient indicator of financial resilience.
  • The available information is limited to the audit report's headline findings, so detailed funding plans and operational implications are still unclear.

Company's press release (SEC filing): Lisata Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Lisata Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →